Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course treatment study for drug-susceptible tuberculous meningitis in children
ChiCTR2400090231Phase 4Not yet recruiting
- Sponsor
- Kunming Children's Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of isoniazid, rifampicin, pyrazinamide, ethambutol and levofloxacin in meningeal tuberculosis (2 arms), sponsored by Kunming Children's Hospital. Primary endpoint: Clinical symptom indicators. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
isoniazidrifampicinpyrazinamideethambutollevofloxacin
03
Conditions
meningeal tuberculosis
Beyond the preview
Go deeper on ChiCTR2400090231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090231.